96 Tests PN: B113334

Components:

45x Ab-conjugated beads (S5P9 - Human sCD27 Ab-bead). PN: B113334A. One vial containing 100 µL of anti-human sCD27 conjugated to AimPlex Bead S5P9.

25x Biotin-detection Ab (Human sCD27 Biotin-dAb). PN: B113334B. One vial containing 100 µL of biotinylated anti- Human sCD27.

Lyophilized Standard Mix - Human sCD27. PN: B113334S. One vial containing lyophilized sCD27.

Application: Optimal antibody pair and antigen standard for assaying human Human CD27/TNFRSF7/sCD27. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 50 pg/mL

  • Quantitation range:

  • LLOQ: < 100 pg/mL

  • ULOQ: > 20,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

CD27 /TNFRSF7 is a receptor for CD70. It is a member of the tumor necrosis factor receptor superfamily and plays a key role in regulating B-cell activation and immunoglobulin synthesis. It is a co-stimulatory receptor expressed on lymphocytes, and is the target of an anti-cancer drug, Varlilumab. The drug is in early clinical trials and appears to stimulate T cells and increase production of cytokines such as interferon-gamma. CD27 has been shown to be a prognostic biomarker in acute myeloid leukemia.

References:

  1. Buchan SL, Rogel A, Al-Shamkhani A (January 2018). "The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy". Blood. 131 (1): 39–48. doi:10.1182/blood-2017-07-741025. PMID 29118006.

  2. Sturgill ER (November 2017). "TNFR agonists: a review of current biologics targeting OX40, 4-1BB, CD27, and GITR". American Journal of Hematology/Oncology. 13 (11).

  3. Riether C, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 2016; 214: 359–380